Bowen disease of the vulva successfully treated with intraarterial infusion chemotherapy

Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan.
Journal of the American Academy of Dermatology (Impact Factor: 4.45). 12/2013; 69(6):e305-6. DOI: 10.1016/j.jaad.2013.08.008
Source: PubMed
Download full-text


Available from: Yi-Shuan Sheen, Mar 12, 2015
3 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sexual function and somatopsychic reactions were examined in 25 women following vulvectomy and in 15 of their partners. More than half of the women had both sexual dysfunction and psychological problems. Their partners had no sexual dysfunction but almost half had psychological problems. An important reason for this seems to be insufficient information and advice both pre- and postoperatively and failure to recognize a developing stricture of the introitus vaginae. Frequent control and advice to both partners both pre- and postoperatively is desirable. Less extensive surgical procedures in selected cases should be considered.
    Acta Obstetricia Et Gynecologica Scandinavica 02/1986; 65(1):7-10. DOI:10.3109/00016348609158221 · 2.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intraepithelial neoplasia of the vulva is being seen with increasing frequency. Awareness of this should prompt the clinician to carefully inspect the vulva on all patients. Reports strongly suggest a relationship between infection with human papillomavirus and vulvar intraepithelial neoplasia. The frequency with which this disease progresses to invasive carcinoma is unknown at present. However, it is obvious that it does occur. Both the warty and basaloid types of vulvar intraepithelial neoplasia are associated with HPV infection and are often associated with invasive squamous cell carcinoma of the vulva demonstrating similar morphologic characteristics. These changes are seen more often in younger women who smoke than in the older nonsmoking woman whose lesions do not appear to be HPV related. Both local excision and the carbon dioxide laser are effective for treating vulvar intraepithelial neoplasia. The choice of which approach to take depends upon the location and size of the lesion or lesions. Whichever approach is utilized, preservation of the normal vulvar anatomy and function are of paramount importance.
    Gynecologic Oncology 02/1995; 56(1):8-21. DOI:10.1006/gyno.1995.1003 · 3.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To establish the true natural history of VIN III from literature data. In a systematic review, data of women with VIN III indexed in several computer databases were pooled. The effect of treatment was correlated with recurrences and progression of VIN III. Ninety-seven articles met the inclusion criteria. Data of 3322 patients were available. The mean age at diagnosis of VIN III was 46. This decreased over time, although not significantly (P = 0.08). Recurrences were seen as often after local excision as after vulvectomy. The percentage of recurrences was lower, but not absent, after free surgical margins than after involved surgical margins (P < 0.001). 6.5% of the 3322 patients progressed to an invasive vulvar carcinoma. Occult carcinomas were diagnosed in 3.2% of patients and 3.3% carcinomas were diagnosed during follow-up. The mean age at diagnosis of invasive vulvar carcinoma was 52 years. Nine percent of 88 untreated patients progressed in 12 to 96 months to invasive vulvar carcinoma. Only 1.2% of the 3322 patients showed complete regression, mostly during the first 10 months after diagnosis, 41% of which was related to pregnancy. Evidence exists that VIN III may progress to invasive vulvar carcinoma. However, the available literature suggests that the progression rate to invasive vulvar carcinoma is low. The incidence of invasion as found in this systematic review is probably even too high, because overreporting of (micro)invasive cases cannot be excluded. Only a prospective registration using a standardized pathology examination will provide information about the real natural history of VIN III.
    Gynecologic Oncology 05/2005; 97(2):645-51. DOI:10.1016/j.ygyno.2005.02.012 · 3.77 Impact Factor